RT Journal Article
SR Electronic
T1 Role of IgM and IgA Antibodies in the Neutralization of SARS-CoV-2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.18.20177303
DO 10.1101/2020.08.18.20177303
A1 Klingler, Jéromine
A1 Weiss, Svenja
A1 Itri, Vincenza
A1 Liu, Xiaomei
A1 Oguntuyo, Kasopefoluwa Y.
A1 Stevens, Christian
A1 Ikegame, Satoshi
A1 Hung, Chuan-Tien
A1 Enyindah-Asonye, Gospel
A1 Amanat, Fatima
A1 Baine, Ian
A1 Arinsburg, Suzanne
A1 Bandres, Juan C.
A1 Kojic, Erna Milunka
A1 Stoever, Jonathan
A1 Jurczyszak, Denise
A1 Bermudez-Gonzalez, Maria
A1 Nádas, Arthur
A1 Liu, Sean
A1 Lee, Benhur
A1 Zolla-Pazner, Susan
A1 Hioe, Catarina E.
YR 2020
UL http://medrxiv.org/content/early/2020/12/21/2020.08.18.20177303.abstract
AB Background SARS-CoV-2 has infected millions of people globally. Virus infection requires the receptor-binding domain (RBD) of the spike protein. Although studies have demonstrated anti-spike and - RBD antibodies to be protective in animal models, and convalescent plasma as a promising therapeutic option, little is known about immunoglobulin (Ig) isotypes capable of blocking infection.Methods We studied spike- and RBD-specific Ig isotypes in convalescent and acute plasma/sera using a multiplex bead assay. We also determined virus neutralization activities in plasma, sera, and purified Ig fractions using a VSV pseudovirus assay.Results Spike- and RBD-specific IgM, IgG1, and IgA1 were produced by all or nearly all subjects at variable levels and detected early after infection. All samples displayed neutralizing activity. Regression analyses revealed that IgM and IgG1 contributed most to neutralization, consistent with IgM and IgG fractions’ neutralization potency. IgA also exhibited neutralizing activity, but with lower potency.Conclusion IgG, IgM and IgA are critical components of convalescent plasma used for COVID-19 treatment.Summary of main points IgM, IgG1 and IgA1 antibodies against SARS-CoV-2 spike glycoprotein and its receptor-binding domain are present in convalescent COVID-19 plasma. Like IgG, IgM and IgA contribute to virus neutralization, providing the basis for optimal selection of convalescent plasma for COVID-19 treatment.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the Microbiology Laboratory Clinical Services at the Mount Sinai Health System and the Mount Sinai Health System Translational Science Hub, National Institutes of Health [grant U54TR001433]; the Personalized Virology Initiative supported by institutional funds and philanthropic donations (to V.S.); the Department of Medicine of the Icahn School of Medicine at Mount Sinai Department of Medicine (to S.Z-P., C.E.H.); the Department of Microbiology and the Ward-Coleman estate for endowing the Ward-Coleman Chairs at the Icahn School of Medicine at Mount Sinai (to B.L.), the National Institute of Allergy and Infectious Diseases Centers of Excellence for Influenza Research and Surveillance [contract HHSN272201400008C] (to F.K., V.S.); the Department of Veterans Affairs [Merit Review Grant I01BX003860] (to C.E.H.) and [Research Career Scientist Award 1IK6BX004607] (to C.E.H.); the National Institute of Allergy and Infectious Diseases [grant AI139290] to C.E.H., [grant AI136916] (to V.S.), [grants R01 AI123449, R21 AI1498033] to B.L. K.Y.O. and C.S. were supported by Viral-Host Pathogenesis Training Grant T32 AI07647; K.Y.O. was additionally supported by F31 AI154739. S.I. and C-T. H. were supported by postdoctoral fellowships from CHOT-SG (Fukuoka University, Japan) and the Ministry of Science and Technology (MOST, Taiwan), respectively. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRBs at Mount Sinai Hospital System, Icahn School of Medicine at Mount Sinai, and the James J. Peter VA Medical CenterAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe raw data that support the findings of this study are available from the corresponding author upon request.